Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: A TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)–Thrombolysis in Myocardial Infarction (TIMI) 38 Substudy

• Published in: The American heart journal Vol. 158; no. 3; pp. e21 - e26
• Main Authors: Pride, Yuri B., MD, Wiviott, Stephen D., MD, Buros, Jacqueline L., BS, Zorkun, Cafer, MD, Tariq, M. Umer, BS, Antman, Elliott M., MD, Braunwald, Eugene, MD, Gibson, C. Michael, MS, MD
• Format: Journal Article
• Language: English
• Published: United States Mosby, Inc 01.09.2009; Elsevier Limited
• Subjects: Acute Coronary Syndrome - drug therapy; Acute Coronary Syndrome - therapy; Acute coronary syndromes; Aged; Angioplasty, Balloon, Coronary; Aspirin - therapeutic use; Cardiovascular; Drug therapy; Female; Heart attacks; Humans; Male; Middle Aged; Piperazines - therapeutic use; Platelet Aggregation Inhibitors - therapeutic use; Prasugrel Hydrochloride; Stents; Thiophenes - therapeutic use; Ticlopidine - analogs & derivatives; Ticlopidine - therapeutic use
• ISSN: 0002-8703; 1097-6744
• DOI: 10.1016/j.ahj.2009.06.021

Background Prasugrel led to a significant reduction in ischemic cardiovascular events among patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with stent implantation compared to clopidogrel. Whether this benefit extends to patients undergoing PCI without stent implantation is unknown. Methods In TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38, patients (n = 13 608) undergoing PCI for ACS were randomized to aspirin plus clopidogrel or prasugrel. This postrandomization analysis of a prespecified subgroup was restricted to patients who underwent PCI without stent implantation (n = 569). Results Patients who underwent PCI without stent implantation were older and had a higher incidence of hypertension, diabetes, prior myocardial infarction (MI), prior coronary artery bypass (CABG) surgery, and renal dysfunction than patients who underwent stent implantation. In the group that did not undergo stent implantation, baseline characteristics were similar between patients receiving clopidogrel and prasugrel. The composite of cardiovascular death, nonfatal MI, and nonfatal stroke occurred in 14.2% of patients receiving prasugrel and 17.1% of patients receiving clopidogrel (HR 0.82, P = .27). There were significant reductions favoring prasugrel in the rates of urgent target vessel revascularization (TVR; HR 0.46, P = .040) and any TVR (HR 0.40, P = .009) and a trend toward a reduction in the incidence of nonfatal MI (HR 0.65, P = .11). CABG-related TIMI major bleeding was more frequent among patients receiving prasugrel. There were no significant interactions between treatment and PCI type. Conclusion Among ACS patients who underwent PCI without stent implantation, prasugrel therapy tended to reduce clinical ischemic events and to increase bleeding events to a similar magnitude as among patients who received stents.